The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.

The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo and Yervoy for the treatment of colorectal ...

At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving ...

AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy programme, as per an 18 ...

The European Commission (EC) has granted marketing authorisation for Sandoz ‘s Afqlir, a biosimilar to the reference medicine ...

During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only ...

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it ...

Developed in partnership with CRScube, a renowned South Korean clinical research technology provider, the purpose-built new ...